JP5701752B2 - 抗ｐ２ｘ７ペプチドおよびエピトープ - Google Patents

抗ｐ２ｘ７ペプチドおよびエピトープ Download PDF

Info

Publication number
JP5701752B2
JP5701752B2 JP2011515029A JP2011515029A JP5701752B2 JP 5701752 B2 JP5701752 B2 JP 5701752B2 JP 2011515029 A JP2011515029 A JP 2011515029A JP 2011515029 A JP2011515029 A JP 2011515029A JP 5701752 B2 JP5701752 B2 JP 5701752B2
Authority
JP
Japan
Prior art keywords
antibody
region
receptor
antibodies
functional
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011515029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526249A (ja
JP2011526249A5 (https=
Inventor
ジュリアン・アレクサンダー・バーデン
アンガス・ギドリー−ベアード
Original Assignee
バイオセプター・インターナショナル・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903451A external-priority patent/AU2008903451A0/en
Application filed by バイオセプター・インターナショナル・リミテッド filed Critical バイオセプター・インターナショナル・リミテッド
Publication of JP2011526249A publication Critical patent/JP2011526249A/ja
Publication of JP2011526249A5 publication Critical patent/JP2011526249A5/ja
Application granted granted Critical
Publication of JP5701752B2 publication Critical patent/JP5701752B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2011515029A 2008-07-04 2009-07-03 抗ｐ２ｘ７ペプチドおよびエピトープ Active JP5701752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
AU2008903451 2008-07-04
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014222949A Division JP2015038144A (ja) 2008-07-04 2014-10-31 抗ｐ２ｘ７ペプチドおよびエピトープ

Publications (3)

Publication Number Publication Date
JP2011526249A JP2011526249A (ja) 2011-10-06
JP2011526249A5 JP2011526249A5 (https=) 2013-10-24
JP5701752B2 true JP5701752B2 (ja) 2015-04-15

Family

ID=41465424

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011515029A Active JP5701752B2 (ja) 2008-07-04 2009-07-03 抗ｐ２ｘ７ペプチドおよびエピトープ
JP2014222949A Pending JP2015038144A (ja) 2008-07-04 2014-10-31 抗ｐ２ｘ７ペプチドおよびエピトープ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014222949A Pending JP2015038144A (ja) 2008-07-04 2014-10-31 抗ｐ２ｘ７ペプチドおよびエピトープ

Country Status (12)

Country Link
US (3) US8597643B2 (https=)
EP (1) EP2318438B1 (https=)
JP (2) JP5701752B2 (https=)
KR (1) KR101701300B1 (https=)
CN (1) CN102143978B (https=)
AU (1) AU2009266430B2 (https=)
BR (1) BRPI0915367B8 (https=)
CA (1) CA2729868C (https=)
ES (1) ES2610225T3 (https=)
IL (2) IL210220A (https=)
NZ (1) NZ590146A (https=)
WO (1) WO2010000041A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.
US20180037650A1 (en) * 2015-04-02 2018-02-08 Biosceptre (Uk) Limited Pain Treatment
US12121539B2 (en) 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
MX2019004410A (es) 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
CN112166193A (zh) 2018-05-21 2021-01-01 生物权威（英国）有限公司 具有经修饰的接头结构域的嵌合抗原受体及其用途
BR112023020659A2 (pt) * 2021-04-08 2023-12-05 Biosceptre Aust Pty Ltd Métodos para controlar a atividade de célula imune
JP2025531675A (ja) * 2022-09-14 2025-09-25 バイオセプター （オースト） プロプライエタリー・リミテッド 操作された免疫細胞の富化
CN120166997A (zh) * 2022-09-14 2025-06-17 生物权威(澳大利亚)有限责任公司 检测免疫细胞的方法
CN120187461A (zh) * 2022-09-14 2025-06-20 生物权威(澳大利亚)有限责任公司 免疫细胞的体内检测

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
AU2566595A (en) 1994-05-27 1995-12-21 Glaxo Group Limited P-2x receptors (purinoceptor family)
WO1997006256A2 (en) 1995-08-09 1997-02-20 Institut National De La Sante Et De La Recherche Medicale Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
JP2001521372A (ja) 1996-04-30 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ヒトＰ２ｘ４レセプタースプライス−変異体
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP1086223B1 (en) 1998-06-01 2009-07-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
WO2002047306A1 (en) * 2000-12-06 2002-06-13 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
JP4384852B2 (ja) 2001-01-17 2009-12-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置
CN100497386C (zh) 2001-09-03 2009-06-10 因特里特有限公司 非功能性p2x7受体的抗体及其应用
EP1469072B1 (en) 2003-04-17 2007-08-29 Affectis Pharmaceuticals AG Means and methods for diagnosing and treating affective disorders
CA2607541A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
JP2010505426A (ja) 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
WO2008043146A1 (en) * 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
ES2619681T3 (es) 2007-09-14 2017-06-26 Biosceptre (Aust) Pty Ltd Novedosos epítopos P2X7
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2467404B1 (en) 2009-08-20 2015-09-30 Biosceptre International Limited Anti p2x7 receptor antibodies and fragments thereof
WO2011075789A1 (en) 2009-12-24 2011-06-30 Biosceptre International Limited Antibodies to non-functional oligomeric p2x7 receptors
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
EP2613808B1 (en) 2010-09-10 2017-11-08 Biosceptre (Aust) Pty Ltd Companion animal cancer treatments with an anti p2x7 antibody
MX349321B (es) 2011-07-01 2017-07-21 Biosceptre (Aust) Pty Ltd Terapia combinada.

Also Published As

Publication number Publication date
US8597643B2 (en) 2013-12-03
US20160199442A1 (en) 2016-07-14
AU2009266430A1 (en) 2010-01-07
BRPI0915367B1 (pt) 2020-10-13
CA2729868A1 (en) 2010-01-07
US10238716B2 (en) 2019-03-26
US20140135475A1 (en) 2014-05-15
WO2010000041A1 (en) 2010-01-07
BRPI0915367A2 (pt) 2015-11-03
NZ590146A (en) 2012-09-28
EP2318438A1 (en) 2011-05-11
AU2009266430B2 (en) 2014-08-14
IL210220A (en) 2016-04-21
JP2015038144A (ja) 2015-02-26
CN102143978A (zh) 2011-08-03
KR20110031222A (ko) 2011-03-24
KR101701300B1 (ko) 2017-02-01
CA2729868C (en) 2018-07-10
US9328155B2 (en) 2016-05-03
US20110110959A1 (en) 2011-05-12
EP2318438B1 (en) 2016-11-02
JP2011526249A (ja) 2011-10-06
IL232394A0 (en) 2014-06-30
AU2009266430A8 (en) 2011-03-10
ES2610225T3 (es) 2017-04-26
IL232394A (en) 2016-04-21
EP2318438A4 (en) 2012-11-21
CN102143978B (zh) 2015-02-18
IL210220A0 (en) 2011-03-31
BRPI0915367B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
JP5701752B2 (ja) 抗ｐ２ｘ７ペプチドおよびエピトープ
JP6417016B2 (ja) 抗ｐ２ｘ７受容体抗体およびその断片
TWI453031B (zh) Ｆｃ受體結合蛋白
JP5992831B2 (ja) 非機能性オリゴマーｐ２ｘ７受容体に対する抗体
IL290412B2 (en) New monoclonal antibodies to cd47 and their uses
ES2811274T3 (es) Anticuerpos monoclonales humanizados y quiméricos para CD99
BR112021008332A2 (pt) composição farmacêutica, proteína de fusão, anticorpo que se liga ao cd47 humano, e, métodos para tratar uma doença em um sujeito humano, para aumentar a seletividade de ligação de um anticorpo monoclonal ou biespecífico ao cd47 humano e para ligar um anticorpo cd47 ao cd47 humano
WO2020098232A1 (en) Fusion Proteins Containing CD47 Antibodies and Cytokines
KR20230147624A (ko) 면역조절 항체 및 이의 용도
TW202311293A (zh) 免疫療法之組合及其用途
HK1152046A (en) Anti-p2x7 peptides and epitopes
HK1152046B (en) Anti-p2x7 peptides and epitopes
CN117062835A (zh) 免疫调节性抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120702

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141031

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141215

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150119

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20150218

R150 Certificate of patent or registration of utility model

Ref document number: 5701752

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250